Carlyle and Leading Healthcare-Focused Venture Finds Announce Strategic Growth Investment of up to $430 Million in Saama

Saama Technologies announced that funds led by global investment firm Carlyle have made a strategic growth investment and will acquire a majority stake in the company. A broad co-investor group with several healthcare-focused venture funds including Amgen Ventures, Intermountain Ventures, Merck Global Health Innovation Fund, McKesson Ventures, Northpond Ventures, Pfizer Ventures, and Population Health Partners, will be investing alongside Carlyle.

The partnership will allow Saama to accelerate its strategic initiatives including expanding its go-to-market capabilities and further investing in AI research and development.

Saama’s intelligent Life Science Analytics Cloud (LSAC) is used by more than 50 pharma and biotech companies on more than 1,500 studies. As an end-to-end platform, LSAC provides a unified approach to clinical trial data management and analytics. LSAC’s pre-trained AI embedded smart applications have the ability to learn the complex patterns among clinical data and provide predictive insights to accelerate the clinical research process across a variety of domains and therapeutic areas.

“The life sciences industry is experiencing a massive shift in strategic approaches to accelerating drug development as a result of the COVID-19 pandemic, and AI-driven analytics solutions like Saama’s LSAC are in the forefront. These solutions’ role in successfully enabling the delivery of COVID-19 vaccines and therapies to patients in mere months was the litmus test for the future of drug development,” said Saama Technologies Founder and CEO Suresh Katta. “This investment by Carlyle and leading healthcare-focused venture funds reflects the value they see in Saama’s leadership of this new era and the promise offered by our state-of-the-art solutions.”

The investment in Saama is a continuation of Carlyle’s long-term global commitment to both healthcare and technology, in which it has invested $17 billion and $25 billion of equity since inception, respectively, including $2 billion in healthcare technology and tech-enabled growth companies.

Read the full press release on BusinessWire.